FDA Recruitment Push Stalls as Overwhelmed HR Operations Slow Hiring Campaign
An administrative bottleneck within the U.S. Food and Drug Administration's human resources center is delaying efforts to recruit thousands of new regulatory and scientific personnel.
By The Global Wire Newsroom · Reported from Margaret Manto
Link preview · horizonglobalnews.com
FDA Recruitment Push Stalls as Overwhelmed HR Operations Slow Hiring Campaign
An administrative bottleneck within the U.S. Food and Drug Administration's human resources center is delaying efforts to recruit thousands of new regulatory and scientific personnel.
A major campaign to rebuild the workforce of the U.S. Food and Drug Administration has run into severe administrative obstacles, as an overwhelmed human resources department struggles to process thousands of job applications. According to reporting by Margaret Manto on September 17, 2026, the federal regulatory agency's efforts to onboard thousands of new employees are being significantly delayed by structural bottlenecks within its central personnel operations center. The recruitment drive was launched to strengthen scientific review teams, enhance food safety monitoring, and accelerate medical technology evaluations. However, the internal human resources unit tasked with managing candidate recruitment, screening, background checks, and formal job offers lacks the operational capacity to handle the massive volume of incoming hires, creating a persistent bottleneck across the organization.
Key facts
What happened
The Food and Drug Administration initiated a broad recruitment campaign aimed at expanding its technical and regulatory workforce by several thousand positions. The initiative was designed to address lingering vacancies across major operating divisions, including the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the newly reorganized Human Foods Program. The agency sought to recruit specialized personnel such as toxicologists, biostatisticians, medical officers, field inspectors, and data science experts to handle increasingly complex regulatory filings.
However, as reported by Margaret Manto, the application surge quickly surpassed the administrative capacity of the agency's central human resources operation. Federal employment procedures require exhaustive administrative processing for every prospective hire. Human resources personnel must review qualifications against strict federal General Schedule criteria, verify academic credentials, execute specialized pay authority determinations, negotiate salary offers, and coordinate security clearance background checks.
As thousands of applicants entered the pipeline, the central human resources center became a major operational bottleneck. Personnel specialists faced mounting caseloads, causing extended delays between initial candidate selection by hiring managers and the issuance of formal tentative job offers. In many cases, candidates who completed technical interviews faced months of administrative silence while their paperwork awaited processing by human resources staff. The administrative slowdown has led to increased candidate drop-out rates, as qualified scientists and medical professionals accept alternative job offers in the private sector while waiting for federal hiring clearances.
Why it matters
The administrative slowdown within the FDA's human resources center carries direct consequences for public health administration, biopharmaceutical development, and regulatory oversight efficiency. The agency operates under strict statutory timelines mandated by Congress through user fee reauthorization agreements. Under programs such as the Prescription Drug User Fee Act, the Biosimilar User Fee Act, and the Medical Device User Fee Amendments, commercial developers pay regulatory fees in exchange for predictable review performance metrics. When review centers remain understaffed due to human resources backlogs, the agency faces heightened pressure in meeting these statutory deadlines for approving new medicines, vaccines, and medical devices.
Furthermore, public health surveillance relies on robust staffing levels across field inspection units and post-market safety divisions. Delayed hiring for food safety inspectors and facility auditors reduces the agency's capacity to conduct routine inspections of foreign and domestic manufacturing plants, potentially increasing vulnerabilities in food and medical supply chains.
The hiring friction also places the federal government at a competitive disadvantage against private industry. The biotechnology, pharmaceutical, and health technology sectors actively compete for the same specialized talent pool, including biostatisticians, bioinformaticians, and clinical pharmacologists. When federal human resources processes delay hiring decisions by several months, top-tier scientific candidates frequently choose private sector positions that offer expedited onboarding, creating a persistent quality and staffing deficit within regulatory agencies.
The background
The Food and Drug Administration has long wrestled with human resources challenges stemming from the complexity of federal hiring rules and pay scale disparities with the private sector. Historically, standard federal employment procedures governed by Title 5 of the United States Code made it difficult for regulatory agencies to offer compensation packages competitive with private pharmaceutical companies or research universities.
To address this systemic problem, Congress enacted the 21st Century Cures Act in December 2016. Section 3072 of the statute granted the FDA specialized hiring authority—often referred to as Cures hiring authority—allowing the agency to streamline recruitment and offer higher pay bands for high-demand scientific and medical positions. This authority was intended to give the FDA flexibility to recruit top experts in specialized fields such as gene therapy, oncology, artificial intelligence, and advanced manufacturing.
In 2022, Congress reauthorized major user fee programs through Fiscal Year 2027 under the Prescription Drug User Fee Act (PDUFA VII) and related statutes. These agreements explicitly authorized funding for hundreds of new full-time equivalent positions dedicated to evaluating complex biologics, cell therapies, and digital health devices. Concurrently, the agency undertook a major structural overhaul of its food safety division, culminating in the creation of a unified Human Foods Program aimed at strengthening oversight following nationwide infant formula shortages and foodborne illness outbreaks.
Despite these expanded statutory authorities and funding streams, the agency's internal administrative infrastructure remained constrained. Personnel management within the Department of Health and Human Services (HHS), the FDA's parent cabinet department, relies heavily on centralized human resources centers and shared services platforms. Over successive years, administrative staffing within these support centers failed to scale proportionally with the expanding regulatory mandates and recruitment budgets granted to technical review divisions, creating the structural vulnerability exposed during the current hiring push.
Reaction
The revelation of hiring delays driven by human resources bottlenecks is expected to draw close oversight from federal lawmakers and industry stakeholders. Members of key congressional committees—including the House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions Committee—frequently review FDA operational efficiency and personnel management during annual budget hearings and statutory reauthorization cycles. Lawmakers have historically expressed concern over unfilled vacancies at regulatory agencies, particularly when authorized user fee funds remain unspent due to administrative hiring friction.
Industry trade groups, including the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), monitor FDA staffing metrics closely. Industry representatives consistently emphasize that meeting regulatory review targets depends directly on the agency's ability to recruit and retain qualified review staff.
Within the federal workforce, union representatives such as the National Treasury Employees Union, which represents non-supervisory FDA employees, have continuously advocated for increased support staff funding and streamlined operational workflows to prevent workplace burnout among existing employees who must absorb extra workloads while vacancies remain unfilled.
What we don't know yet
Several key details regarding the extent and resolution of the hiring slowdown remain unconfirmed in current reporting:
What to watch
Key developments to monitor in the coming months include:
This report is based on original news reporting published by Margaret Manto on September 17, 2026.
How this story was produced
This report was written by The Global Wire newsroom from reporting first published by Margaret Manto. We verify the core facts against the original report, write our own account, and add the background and consequences a short wire item leaves out. Drafting is AI-assisted inside an editor-supervised pipeline, and every story is checked for accuracy of attribution, structure and duplication before it appears — full detail in our AI and funding disclosure.
Spotted an error? Tell us at corrections@horizonglobalnews.com and read our corrections policy or editorial standards.
Reader comments
Loading comments…